Fungal Infection: Diagnosis and Management, Fourth Edition

Fungal Infection: Diagnosis and Management, Fourth Edition

Volumn , Issue , 2012, Pages

  Richardson, Malcolm D ^a,b   Warnock, David W ^c  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886831629     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118321492     Document Type: Book

References (367)

1. Alangaden, G.J. (2011) Nosocomial fungal infections: epidemiology, infection control, and prevention. Infectious Diseases Clinics of North America 25, 201-225.
2. Balajee, S.A., Borman, A.M., Brandt, M.E., et al. (2009) Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here. Journal of Clinical Microbiology 47, 877-884.
3. Denning, D.W. & Hope, W.W. (2010) Therapy for fungal diseases: opportunities and priorities. Trends in Microbiology 18, 195-204.
4. Kontoyiannis, D.P., Marr, K.A., Park, B.J., et al. (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clinical Infectious Diseases 50, 1091-1100.
5. Odds, F.C., Arai, T., DiSalvo, A.F., et al. (1992) Nomenclature of fungal diseases: a report and recommendations from a sub-committee of the International Society for Human and Animal Mycology (ISHAM). Journal of Medical and Veterinary Mycology 30, 1-10.
6. Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J.N., et al. (2010) An insight into the antifungal pipeline: selected new molecules and beyond. Nature Reviews Drug Discovery 9, 719-727.
7. Panackal, A.A., Hajjeh, R.A., Cetron, M.S., et al. (2002) Fungal infections among returning travellers. Clinical Infectious Diseases 35, 1088-1095.
8. Pappas, P.G. (2010) Opportunistic fungi: a view to the future. American Journal of the Medical Sciences 340, 253-257.
9. Pappas, P.G., Alexander, B.D., Andes, D.A., et al. (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clinical Infectious Diseases 50, 1101-1111.
10. Park, B.J., Wannemuehler, K.A., Marston, B.J., et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23, 525-530.
11. Pfaller, M.A. & Diekema, D.J. (2010) Epidemiology of invasive mycoses in North America. Critical Reviews in Microbiology 36, 1-53.
12. Warnock, D.W. (2006) Fungal diseases: an evolving public health challenge. Medical Mycology 44, 697-705.
13. Balajee, S.A., Borman, A.M., Brandt, M.E., et al. (2009) Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here. Journal of Clinical Microbiology 47, 877-884.
14. Barnes, R.A., White, P.L., Bygrave, C., et al. (2009) Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. Journal of Clinical Pathology 62, 64-69.
15. Clinical and Laboratory Standards Institute (2008) Interpretive Criteria for Identification of Bacteria and Fungi by DNA Target Sequencing; Approved Guideline. CLSI document MM18-A. Clinical and Laboratory Standards Institute, Wayne, PA.
16. Cuenca-Estrella, M., Bassetti, M., Lass-Florl, C., et al. (2011) Detection and investigation of invasive mould disease. Journal of Antimicrobial Chemotherapy 66(suppl. 1), i15-i24.
17. Denning, D.W., Kibbler, C.C. & Barnes, R.A. (2003) British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infectious Diseases 3, 230-240.
18. De Pauw, B.,Walsh, T.J., Donnelly, J.P., et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases 46, 1813-1821.
19. Guarner, J. & Brandt, M.E. (2011) Histopathologic diagnosis of fungal infections in the 21st century. Clinical Microbiology Reviews 24, 247-280.
20. Hsu, J.L., Ruoss, S.J., Bower, N.D., et al. (2011) Diagnosing invasive fungal disease in critically ill patients. Critical Reviews in Microbiology 37, 277-312.
21. Karageorgopoulos, D.E., Vouloumanou, E.K., Ntziora, F., et al. (2011) Β-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clinical Infectious Diseases 52, 750-770.
22. Klutts, J.S. & Robinson-Dunn, B. (2011) A critical appraisal of the role of the clinical microbiology laboratory in diagnosis of invasive fungal infections. Journal of Clinical Microbiology 49 (Suppl), S39-S42.
23. Koo, S., Bryar, J.M., Page, J.H., et al. (2009) Diagnostic performance of the (1-3)-dglucan assay for invasive fungal diseases. Clinical Infectious Diseases 49, 1650-1659.
24. Lau, A., Chen, S., Sleiman, S., et al. (2009). Current status and future perspectives on molecular and serological methods in diagnostic mycology. Future Microbiology 4, 1185-1222.
25. Procop, G.W. (2010) Molecular diagnostics for invasive fungal infections: a call for refinement and implementation. Journal of Molecular Diagnostics 12, 17-19.
26. Westh, H., Lisby, G., Breysse, F., et al. (2009). Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clinical Microbiology and Infection 15, 544-551.
27. White, P.L., Bretagne, S., Klingspor, L., et al. (2010) Aspergillus PCR: one step closer to standardization. Journal of Clinical Microbiology 48, 1231-1240.
28. Andes, D., Pascual, A. & Marchetti, O. (2009) Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrobial Agents and Chemotherapy 53, 24-34.
29. Bruggemann, R.J., Alffenaar, J.W., Blijlevens, N.M., et al. (2009) Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clinical Infectious Diseases 48, 1441-1458.
30. Chen, S.C., Slavin, M.A. & Sorrell, T.C. (2011) Echinocandin fungal drugs in fungal infections. Drugs 71, 11-41.
31. Cross, S.A. & Scott, L.J. (2008) Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidosis, and as prophylaxis against Candida infections. Drugs 68, 2225-2255.
32. Frampton, J.E. & Scott, L.J. (2008) Posaconazole: a review of its use in the prophylaxis of invasive fungal infections. Drugs 68, 993-1016.
33. Girmenia, C. (2009) New generation azole antifungals in clinical investigation. Expert Opinion in Infectious Diseases 18, 1279-1295.
34. Howard, S.J. & Arendrup, M.C. (2011) Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Medical Mycology 49(Suppl. 1), S90-S95.
35. Hussaini, T., Ruping, M.J., Farowski, F., et al. (2011) Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 31, 214-225.
36. Krishnan-Natesan, S. (2009) Terbinafine: a pharmacological and clinical review. Expert Opinion in Pharmacotherapy 10, 2723-2733.
37. Kuti, E.L. & Kuti, J.L. (2010) Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. Expert Opinion in Drug Metabolism and Toxicology 6, 1287-1300.
38. Kwon, D.S. & Mylonakis, E. (2007) Posaconazole: a new broad-spectrum antifungal agent. Expert Opinion in Pharmacotherapy 8, 1167-1178.
39. Maertens, J. & Boogaerts, M. (2005) The place for itraconazole in treatment. Journal of Antimicrobial Chemotherapy 56(Suppl. 1), 33-38.
40. Marr, K.A. (2008) Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Current Opinion in Infectious Diseases 21, 409-414.
41. Moen, M.D., Lyseng-Williamson, K.A. & Scott, L.J. (2009) Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs 69, 361-392.
42. Ostrosky-Zeichner, L., Marr, K.A., Rex, J.H., et al. (2003) Amphotericin B: time for a new 'gold standard'. Clinical Infectious Diseases 37, 415-425.
43. Playford, E.G., Webster, A.C., Sorrell, T.C., et al. (2006) Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. Journal of Antimicrobial Chemotherapy 57, 628-638.
44. Scott, L.J. & Simpson, D. (2007) Voriconazole: a review of its role in the management of invasive fungal infections. Drugs 67, 269-298.
45. Thompson, G.R. & Lewis, J.S. (2010) Pharmacology and clinical use of voriconazole. Expert Opinion in Drug Metabolism and Toxicology 6, 83-94.
46. Vermes, A., Guchelaar, H.J. & Dankert, J. (2000) Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. Journal of Antimicrobial Chemotherapy 46, 171-179.
47. Wiederhold, N.P. & Lewis, J.S. (2007) The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opinion in Pharmacotherapy 8, 1155-1166.
48. Wingard, J.R., Carter, S.L., Walsh, T.J., et al. (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116, 5111-5118.
49. Ziakis, P.D., Kourbeti, I.S., Voulgarelis, M., et al. (2010) Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials. Clinical Therapeutics 32, 2316-2336.
50. Abdel-Rahman, S.M., Farrand, N., Schuenemann, E., et al. (2010) The prevalence of infections with Trichophyton tonsurans in schoolchildren: the CAPITIS study. Pediatrics 125, 966-973.
51. Borman, A.M., Campbell, C.K., Fraser, M., et al. (2007) Analysis of the dermatophyte species isolated in the British Isles between 1980 and 2005 and review of worldwide dermatophyte trends over the last three decades. Medical Mycology 45, 131-141.
52. De Berker, D. (2009) Fungal nail disease. New England Journal of Medicine 360, 2108-2116.
53. Elewski, B.E., Caceres, H.W., DeLeon, L., et al. (2008) Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. Journal of the American Academy of Dermatology 59, 41-54.
54. Field, L.A. & Adams, B.B. (2008) Tinea pedis in athletes. International Journal of Dermatology 47, 485-492.
55. Fuller, L.C. (2009) Changing face of tinea capitis in Europe. Current Opinion in Infectious Diseases 22, 115-118.
56. Gonzalez, U., Seaton, T., Bergus, G., et al. (2007) Systemic antifungal therapy for tinea capitis in children. Cochrane Database of Systematic Reviews 17(4), CD004685, DOI: 10.1002/14651858.CD004685.pub2.
57. Ginter-Hanselmayer, G., Weger, W., Ilkit, M., et al. (2007) Epidemiology of tinea capitis in Europe: current state and changing patterns. Mycoses 50(Suppl. 2), 6-13.
58. Graser, Y., Scott, J. & Summerbell, R.C. (2008) The new species concept in dermatophytes: a polyphasic approach. Mycopathologia 166, 239-256.
59. Gupta, A.K. & Cooper, E.A. (2008) Update in antifungal therapy of dermatophytosis. Mycopathologia 166, 353-367.
60. Roberts, D.T., Taylor,W.D. & Boyle, J. (2003). Guidelines for treatment of onychomycosis. British Journal of Dermatology 148, 402-410.
61. Sigurgeirsson, B., Olafsson, J.H., Steinsson, J.B., et al. (2002) Long-term effectiveness of treatment with terbinafine v. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Archives of Dermatology 138, 353-357.
62. Tavakkol, A., Fellman, S. & Kianifard, F. (2006) Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial. American Journal of Geriatric Pharmacotherapy 4, 1-13.
63. Warshaw, E.M., Fett, D.D., Bloomfield, H.E. et al. (2005) Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. Journal of the American Academy of Dermatology 53, 575-584.
64. Centers for Disease Control and Prevention (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 58(RR-4), 1-207.
65. De Berker, D. (2010) Fungal nail disease. New England Journal of Medicine 360, 2108-2116.
66. Fichtenbaum, C.J., Koletar, S., Yiannoutsos, C., et al. (2000) Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clinical Infectious Diseases 30, 749-756.
67. Goldman, M., Cloud, G.A., Wade, K.D., et al. (2005) A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis. Clinical Infectious Diseases 41, 1473-1480.
68. Pappas, P.G., Kauffman, C.A., Andes, D., et al. (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 48, 503-535.
69. Roberts, D.T., Taylor,W.D. & Boyle, J. (2003) Guidelines for the treatment of onychomycosis. British Journal of Dermatology 148, 402-410.
70. Sobel, J.D. (2002) Pathogenesis of recurrent vulvovaginal candidiasis. Current Infectious Disease Reports 4, 514-519.
71. Sobel, J.D. (2006) Management of recurrent vulvovaginal candidiasis: unresolved issues. Current Infectious Disease Reports 8, 481-486.
72. Sobel, J.D., Chaim,W., Nagappan, V., et al. (2003) Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. American Journal of Obstetrics and Gynecology 189, 1297-1300.
73. Sobel, J.D.,Wiesenfeld, H.C., Martens, M., et al. (2004) Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine 351, 876-883.
74. Vazquez, J.A. (2007) Posaconazole for the management of mucosal candidiasis. Future Microbiology 2, 245-256.
75. Ashbee, H.R. (2007) Update on the genus Malassezia. Medical Mycology 45, 287-303.
76. Chagas-Neto, T.C., Chaves, G.M. & Colombo, A.L. (2008) Update on the genus Trichosporon. Mycopathologia 166, 121-132.
77. Gupta, A.K., Batra, R., Bluhm, R., et al. (2004) Skin diseases associated with Malassezia species. Journal of the American Academy of Dermatology 51, 785-798.
78. Gupta, A.K., Nicol, K. & Batra, R. (2004) Role of antifungal agents in the treatment of seborrhoeic dermatitis. American Journal of Clinical Dermatology 5, 417-422.
79. Hay, R.J. (2002) Scytalidium infections. Current Opinion in Infectious Diseases 15, 99-100.
80. Kiken, D.A., Sekaran, A., Antaya, R.J., et al. (2006) White piedra in children. Journal of the American Academy of Dermatology 55, 956-961.
81. Lacroix, C., Kac, G., Dubertret, L., et al. (2003) Scytalidiosis in Paris, France. Journal of the American Academy of Dermatology 48, 852-856.
82. Lyke, K.E., Miller, N.S., Towne, L., et al. (2001) A case of cutaneous ulcerative alternariosis: rare association with diabetes mellitus and unusual failure of itraconazole treatment. Clinical Infectious Diseases 32, 1178-1187.
83. Pastor, F.J. & Guarro, J. (2008) Alternaria infections: laboratory diagnosis and relevant clinical features. Clinical Microbiology and Infection 14, 734-746.
84. Schwartz, R.A. (2004) Superficial fungal infections. Lancet 364, 1173-1182.
85. De Berker, D. (2009) Fungal nail disease. New England Journal of Medicine 360, 2108-2116.
86. Finch, J.J. &Warshaw, E.M. (2007) Toenail onychomycosis: current and future treatment options. Dermatologic Therapy 20, 31-46.
87. Gupta, A.K., Gregurek-Novak, T., Konnikov, N., et al. (2001) Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. Journal of Cutaneous Medicine and Surgery 5, 206-210.
88. Kumar, S. & Kimball, A.B. (2009) New antifungal therapies for the treatment of onychomycosis. Expert Opinion in Investigational Drugs 18, 727-734.
89. Lacroix, C., Kac, G., Dubertret, L., et al. (2003) Scytalidiosis in Paris, France. Journal of the American Academy of Dermatology 48, 852-856.
90. Roberts, D.T., Taylor, W.D. & Boyle, J. (2003) Guidelines for treatment of onychomycosis. British Journal of Dermatology 148, 402-410.
91. Summerbell, R.C., Cooper, E., Bunn, U., et al. (2005) Onychomycosis: a critical study of techniques and criteria for confirming the etiologic significance of nondermatophytes. Medical Mycology 43, 39-59.
92. Tosti, A., Piraccini, B.M. & Lorenzi, S. (2000) Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. Journal of the American Academy of Dermatology 42, 217-224.
93. Chang, D.C., Grant, G.B., O'Donnell, K., et al. (2006) Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. Journal of the American Medical Association 296, 953-963.
94. Gower, E.W., Keay, L.J., Oechsler, R.A., et al. (2010) Trends in fungal keratitis in the United States, 2001 to 2007. Ophthalmology 117, 2263-2267.
95. Hariprasad, S.M., Mieler, W.F., Lin, T.K., et al. (2008) Voriconazole in the treatment of fungal eye infections: a review of current literature. British Journal of Ophthalmology 92, 871-878.
96. Thomas, P.A. (2003) Current perspectives on ophthalmic mycoses. Clinical Microbiology Reviews 16, 730-797.
97. Ho, T., Vrabec, J.T., Yoo, D., et al. (2006) Otomycosis: clinical features and treatment implications. Otolaryngology: Head and Neck Surgery 135, 787-791.
98. Hurst, W.B. (2001) Outcome of 22 cases of perforated tympanic membrane caused by otomycosis. Journal of Laryngology and Otology 115, 879-880.
99. Jackman, A., Ward, R., April, M., et al. (2005) Topical antibiotic-induced otomycosis. International Journal of Pediatric Otorhinolaryngology 69, 857-860.
100. Munguia, R. & Daniel, S.J. (2007) Ototopical antifungals and otomycosis: a review. International Journal of Pediatric Otorhinolaryngology 72, 453-459.
101. Vennewals, I. & Klemm, E. (2010) Otomycosis: diagnosis and treatment. Clinics in Dermatology 28, 202-211.
102. Yao, M. & Messner, A.H. (2001) Fungal malignant otitis externa due to Scedosporium apiospermum. Annals of Otology, Rhinology and Laryngology 110, 377-380.
103. Centers for Disease Control and Prevention. (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Morbidity and Mortality Weekly Report 49(RR-10), 1-125.
104. Centers for Disease Control and Prevention. (2003) Guidelines for environmental infection control in healthcare facilities. Morbidity and Mortality Weekly Report 52(RR-10), 1-42.
105. Chakrabarti, A., Denning, D.W., Ferguson, B.J., et al. (2009) Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope 119, 1809-1818.
106. Cornely, O.A., Maertens, J., Bresnik, M., et al. (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clinical Infectious Diseases 44, 1289-1297.
107. Denning, D.W., Riniotis, K., Dobrashian, R., et al. (2003) Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclatural change, and review. Clinical Infectious Diseases 37(Suppl. 3), S265-S280.
108. De Pauw, B.E. & Donnelly, J.P. (2007) Prophylaxis and aspergillosis: has the principle been proven? New England Journal of Medicine 356, 409-411.
109. Glasmacher A., Prentice A., Gorschluter, M., et al. (2003) Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies; evidence from a meta-analysis of 3,597 patients. Journal of Clinical Oncology 21, 4615-4626.
110. Greene, R.E., Schlamm, H.T., Oestmann, J.W., et al. (2007) Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clinical Infectious Diseases 44, 373-379.
111. Guo, Y.L., Chen, Y.Q.,Wang, K., et al. (2010) Accuracy of bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review. Chest 138, 817-824.
112. Herbrecht, R., Denning, D.W., Patterson, T.F., et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine 347, 408-415.
113. Herbrecht, R., Maertens, J., Baila, L., et al. (2010) Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organization for Research and Treatment of Cancer study. Bone Marrow Transplantation 45, 1227-1233.
114. Hope, W.W., Walsh, T.J. & Denning, D.W. (2005) The invasive and saprophytic syndromes due to Aspergillus spp. Medical Mycology 43(Suppl. 1), S207-S208.
115. Mengoli, C., Cruciani, M., Barnes, R.A., et al. (2009) Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infectious Diseases 9, 89-96.
116. Morgan, J., Wannemuehler, K.A., Marr, K.A., et al. (2005) Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Medical Mycology 43(Suppl. 1), S49-S58.
117. Nguyen, M.H., Leather, H., Clancy, C.J., et al. (2011) Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biology of Blood and Marrow Transplantation 17, 1043-1050.
118. Nivoix, Y., Velten, M., Letscher-Bru, V., et al. (2008) Factors associated with overall and attributable mortality in invasive aspergillosis. Clinical Infectious Diseases 47, 1176-1184.
119. Pagano, L., Caira, M., Picardi, M., et al. (2007) Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality-SEIFEM-C report. Clinical Infectious Diseases 44, 1524-1525.
120. Pfeiffer, C.D., Fine, J.P. & Safdar, N. (2006) Diagnosis of aspergillosis using a galactomannan assay: a meta-analysis. Clinical Infectious Diseases 42, 1417-1427.
121. Ruhnke, M., Kofla, G., Otto, K., et al. (2007) CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 21, 659-676.
122. Singh, N. & Paterson, D.L. (2005) Aspergillus infections in transplant recipients. Clinical Microbiology Reviews 18, 44-69.
123. Steinbach, W.J., Benjamin, D.K., Kontoyiannis, D.P., et al. (2004) Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clinical Infectious Diseases 39, 192-198.
124. Upton, A., Kirby, K.A., Carpenter, P., et al. (2007) Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clinical Infectious Diseases 44, 531-540.
125. Walsh, T.J., Anaissie, E.J., Denning, D.W., et al. (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases 46, 327-360.
126. Walsh, T.J., Raad, I., Patterson, T.F., et al. (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clinical Infectious Diseases 44, 2-12.
127. Warnock, D.W., Hajjeh, R.A., & Lasker, B.A. (2001) Epidemiology and prevention of invasive aspergillosis. Current Infectious Disease Reports 3, 507-516.
128. White, P.L., Bretagne, S., Klingspor, L., et al. (2010) Aspergillus PCR: one step closer to standardization. Journal of Clinical Microbiology 48, 1231-1240.
129. White, P.L., Perry, M.D., Moody, A., et al. (2011) Evaluation of analytical and preliminary clinical performance of Myconostica MycAssay Aspergillus when testing serum specimens for diagnosis of invasive aspergillosis. Journal of Clinical Microbiology 49, 2169-2174.
130. Wingard, J.R., Carter, S.L., Walsh, T.J., et al. (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116, 5111-5118.
131. Avni, T., Leibovici, L. & Paul, M. (2011) PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. Journal of Clinical Microbiology 49, 665-670.
132. Bassetti, M., Righi, E., Tumbarello, M., et al. (2006) Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Reviews in Anti-Infective Therapy 4, 875-885.
133. Bow, E.J., Laverdiere, M., Lussier, N., et al. (2002) Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 94, 3230-3246.
134. Centers for Disease Control and Prevention. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 58(RR-4), 1-207.
135. Kaufman, D.A. (2010) Challenging issues in neonatal candidiasis. Current Medical Research & Opinion 26, 1769-1778.
136. Koo, S., Bryar, J.M., Page, J.H., et al. (2009) Diagnostic performance of the (1-3)-Β-dglucan assay for invasive fungal disease. Clinical Infectious Diseases 49, 1650-1659.
137. Kuse, E.R., Chetchototisakd, P., da Cunha, C.A., et al. (2007) Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369, 1519-1527.
138. Legrand, F., Lecuit, M., Dupont, B., et al. (2008) Adjuvant corticosteroid therapy for chronic disseminated candidiasis. Clinical Infectious Diseases 46, 696-702.
139. Malani, A.N. & Kauffman, C.A. (2007) Candida urinary tract infections: treatment options. Expert Reviews in Anti-Infective Therapy 5, 277-284.
140. Marr, K.A. (2008) Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Current Opinion in Infectious Diseases 21, 409-414.
141. Nucci, M. & Anaissie, E. (2002) Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clinical Infectious Diseases 34, 591-599.
142. Pappas, P.G., Kauffman, C.A., Andes, D., et al. (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 48, 503-535.
143. Pfaller, M.A. & Diekema, D.J. (2010) Epidemiology of invasive mycoses in North America. Critical Reviews in Microbiology 36, 1-53.
144. Playford, E.G., Eggimann, P.&Calandra, T. (2008) Antifungals in the ICU. Current Opinion in Infectious Diseases 21, 610-619.
145. Playford, E.G., Webster, A.C., Sorrell, T.C., et al. (2006) Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. Journal of Antimicrobial Chemotherapy 57, 628-638.
146. Riddell, J., Comer, G.M. & Kauffman, C.A. (2011) Treatment of endogenous fungal endophthalmitis: focus on new antifungals. Clinical Infectious Diseases 52, 648-653.
147. Shepard, J.R., Addison, R.M., Alexander, B.D., et al. (2008) Multicenter evaluation of the Candida albicans/Candida glabrata peptide nucleic acid fluorescent in situ hybridization method for simultaneous dual-color identification of C. albicans and C. glabrata directly from blood culture bottles. Journal of Clinical Microbiology 46, 50-55.
148. Steinbach,W.J., Perfect, J.R., Cabell, C.H., et al. (2005) A meta-analysis of medical versus surgical therapy for Candida endocarditis. Journal of Infection 51, 230-247.
149. Yera, H., Sendid, B., Francois, N., et al. (2001) Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. European Journal of Clinical Microbiology and Infectious Diseases 20, 864-870.
150. Zaoutis, T. (2010) Candidemia in children. Current Medical Research & Opinion 26, 1761-1768.
151. Centers for Disease Control and Prevention. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 58(RR-4), 1-207.
152. Chang, L.W., Phipps, W.T., Kennedy, G.E., et al. (2005) Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV (review). Cochrane Database of Systematic Reviews (3), CD004773.
153. Jarvis, J.N., Lawn, S.D., Wood, R., et al. (2010) Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clinical Infectious Diseases 51, 1463-1465.
154. Kambugu, A., Meya, D.B., Rhein, J., et al. (2008) Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clinical Infectious Diseases 46, 1694-1701.
155. Kidd, S.E., Bach, P.J., Hingston, A.O., et al. (2007) Cryptococcus gattii dispersal mechanisms, British Columbia, Canada. Emerging Infectious Diseases 13, 51-57.
156. Lin, X. & Heitman, J. (2006) The biology of the Cryptococcus neoformans species complex. Annual Review of Microbiology 60, 69-105.
157. Lindsley, M.D., Mekha, N., Baggett, H.C., et al. (2011) Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clinical Infectious Diseases 53, 321-325.
158. MacDougall, L., Kidd, S.E., Galanis, E., et al. (2007) Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerging Infectious Diseases 13, 42-50.
159. McTaggart, L., Richardson, S.E., Seah, C., et al. (2011) Rapid identification of Cryptococcus neoformans var. grubii, C. neoformans var. neoformans, and C. gattii by use of rapid biochemical tests, differential media, and DNA sequencing. Journal of Clinical Microbiology 49, 2522-2527.
160. Mirza, S.A., Phelan, M., Rimland, D., et al. (2003) The changing epidemiology of cryptococcosis: an update from population-based active surveillance in two large metropolitan areas, 1992-2000. Clinical Infectious Diseases 36, 789-794.
161. Morgan, J., McCarthy, K.M., Gould, S., et al. (2006) Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with a high HIV seroprevalence, 2002-2004. Clinical Infectious Diseases 43, 1077-1080.
162. Pappas, P.G., Perfect, J.R., Cloud, G.A., et al. (2001) Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clinical Infectious Diseases 33, 690-699.
163. Park, B.J., Wannemuehler, K.A., Marston, B.J., et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23, 525-530.
164. Perfect, J.R., Dismukes,W.E., Dromer, F., et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 50, 291-322.
165. Sloan, D.J., Dedicoat, M.J. & Lalloo, D.G. (2009) Treatment of cryptococcal meningitis in resource limited settings. Current Opinion in Infectious Diseases 22, 455-463.
166. Sun, H.Y.,Wagener, M.M. & Singh, N. (2009) Cryptococcosis in solid-organ, hematopoietic stem cell, and tissue transplant recipients: evidence-based evolving trends. Clinical Infectious Diseases 48, 1566-1576.
167. Sungkanuparph, S., Filler, S.G., Chetchotisakd, P., et al. (2009) Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clinical Infectious Diseases 49, 931-934.
168. Visnegarwala, F., Graviss, E.A., Lacke, C.E., et al. (1998) Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clinical Infectious Diseases 27, 1231-1237.
169. Antoniadou, A. (2009) Outbreaks of zygomycosis in hospitals. Clinical Microbiology and Infection 15(Suppl. 5), 55-59.
170. Bitar, D., Van Cauteren, D., Lanternier, F., et al. (2009) Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerging Infectious Diseases 15, 1395-1401.
171. Centers for Disease Control and Prevention. (2003) Guidelines for environmental infection control in health-care facilities. Morbidity and Mortality Weekly Report 52(RR-10), 1-42.
172. Centers for Disease Control and Prevention. (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Morbidity and Mortality Weekly Report 49(RR-10), 1-125.
173. Chamilos, G., Lewis, R.E. & Kontoyiannis, D.P. (2008) Delaying amphotericin B-based front-line therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clinical Infectious Diseases 47, 503-509.
174. Chayakulkeeree, M., Ghannoum, M.A. & Perfect, J.R. (2006) Zygomycosis: the reemerging fungal infection. European Journal of Clinical Microbiology and Infectious Diseases 25, 215-229.
175. Gomes, M.Z., Lewis, R.E.&Kontoyiannis, D.P. (2011) Mucormycosis caused by unusual Mucorymcetes, Non-Rhizopus,-Mucor, and-Lichtheimia species. Clinical Microbiology Reviews 24(2), 411-445.
176. Losee, J.E., Selber, J., Vega, S., et al. (2000) Primary cutaneous mucormycosis: guide to surgical management. Annals of Plastic Surgery 49, 385-390.
177. Ribes, J.A., Vanover-Sams, C.L. & Baker, D.J. (2000) Zygomycetes in human disease. Clinical Microbiology Reviews 13, 236-301.
178. Roden, M.M., Zaoutis, T.E., Buchanan,W.L., et al. (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clinical Infectious Diseases 41, 634-653.
179. Singh, N., Aguado, J.M., Bonati, H., et al. (2009) Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. Journal of Infectious Diseases 200, 1002-1011.
180. Spellberg, B., Edwards J. & Ibrahim, A. (2006) Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clinical Microbiology Reviews 18, 556-569.
181. Symeonidis, A.S. (2009) The role of iron and iron chelators in zygomycosis. Clinical Microbiology and Infection 15(Suppl. 5), 26-32.
182. Van Burik, J.A., Hare, R.S., Solomon, H.F., et al. (2006) Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clinical Infectious Diseases 42, e61-e65.
183. Zaoutis, T.E., Roilides, E., Chiou, C., et al. (2007) Zygomycosis in children: a systematic review and analysis of reported cases. Pediatric Infectious diseases Journal 26, 723-727.
184. Centers for Disease Control and Prevention. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 58(RR-4), 1-207.
185. Cushion, M.T., Linke, M.J., Ashbaugh, A., et al. (2010) Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One 5, e8524.
186. Desmet, S., Van Wijngaerden, E., Maertens, J., et al. (2009) Serum (1-3)-Β-d-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or haematological malignancy. Journal of Clinical Microbiology 47, 3871-3874.
187. Dini, L., du Plessis, M., Frean, J., et al. (2010) High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa. Journal of Clinical Microbiology 48, 2016-2021.
188. Hauser, P.M., Bille, J., Lass-Florl, C., et al. (2011) Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. Journal of Clinical Microbiology 49, 1872-1878.
189. Morris, A., Beard, C.B. & Huang, L. (2002) Update on the epidemiology and transmission of Pneumocystis carinii. Microbes and Infection 4, 95-103.
190. Rohner, P., Jacomo, V., Studer, R., et al. (2009) Detection of Pneumocystis jirovecii by two staining methods and two quantitative PCR assays. Infection 37, 261-265.
191. Smego, R.A., Nagar, S., Maloba, B., et al. (2001) A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Archives of Internal Medicine 161, 1529-1533.
192. Thomas, C.F. & Limper, A.H. (2007) Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nature Reviews Microbiology 5, 298-308.
193. Vargas, S.L., Hughes,W.T., Santolaya, M.E., et al. (2001) Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clinical Infectious Diseases 32, 855-861.
194. Walzer, P.D., Evans, H.E., Copas, A.J., et al. (2008) Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clinical Infectious Diseases 46, 625-633.
195. Walzer, P.D., Djawe, K., Levin, L., et al. (2009) Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection. Journal of Infectious Diseases 199, 1335-1344.
196. Bariola, J.R., Perry, P., Pappas, P.G., et al. (2010) Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clinical Infectious Diseases 50, 797-804.
197. Bradsher, R.W. (2008) Pulmonary blastomycosis. Seminars in Respiratory and Critical Care Medicine 29, 174-181.
198. Cano, M.V., Ponce-de-Leon, G.F., Tippen, S., et al. (2003) Blastomycosis in Missouri: epidemiology and risk factors for endemic disease. Epidemiology and Infection 131, 907-914.
199. Chapman, S.W., Dismukes,W.E., Proia, L.A., et al. (2008) Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 46, 1801-1812.
200. Durkin, M.,Witt, J., LeMonte, A., et al. (2004) Antigen assay with the potential to aid in diagnosis of blastomycosis. Journal of Clinical Microbiology 42, 4873-4865.
201. Fang,W.,Washington, L. & Kumar, N. (2007) Imaging manifestations of blastomycosis: a pulmonary infection with potential dissemination. RadioGraphics 27, 641-655.
202. Lemos, L.B., Baliga, M. & Guo, M. (2001) Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Annals of Diagnostic Pathology 5, 1-9.
203. McKinnell, J.A. & Pappas, P.G. (2009) Blastomycosis: new insights into diagnosis, prevention, and treatment. Clinics in Chest Medicine 30, 229-239.
204. Morris, S.K., Brophy, J., Richardson, S.E., et al. (2006) Blastomycosis in Ontario, 1994-2003. Emerging Infectious Diseases 12, 274-279.
205. Plamondon, M., Lamontagne, F., Allard, C., et al. (2010) Corticosteroids as adjunctive therapy in severe blastomycosis-induced acute respiratory distress syndrome in an immunosuppressed patient. Clinical Infectious Diseases 51, e1-e3.
206. Saccente, M. & Woods, G.L. (2010) Clinical and laboratory update on blastomycosis. Clinical Microbiology Reviews 23, 367-381.
207. Ta, M., Flowers, S.A. & Rogers, P.D. (2009) The role of voriconazole in the treatment of central nervous system blastomycosis. Annals of Pharmacotherapy 43, 1696-1700.
208. Ampel, N.M., Giblin, A., Mourani, J.P., et al. (2009) Factors and outcomes associated with the decision to treat primary pulmonary coccidioidomycosis. Clinical Infectious Diseases 48, 172-178.
209. Blair, J.E. (2008) Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Current Opinion in Infectious Diseases 21, 415-420.
210. Centers for Disease Control and Prevention. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 58(RR-4), 1-207.
211. Crum, N.F., Lederman, E.R., Stafford, C.M., et al. (2004) Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine 83, 149-175.
212. Fisher, M.C., Koenig, G.L., White, T.J., et al. (2002) Molecular and phenotypic description of Coccidioides posadasii sp. nov., previously recognized as the non-California population of Coccidioides immitis. Mycologia 94, 73-84.
213. Freifeld, A., Proia, L., Andes, D., et al. (2009) Voriconazole use for endemic fungal infections. Antimicrobial Agents and Chemotherapy 53, 1648-1651.
214. Galgiani, J.N., Ampel, N.M., Blair, J.E., et al. (2005). Coccidioidomycosis. Clinical Infectious Diseases 41, 1217-1223.
215. Masannat, F.Y. & Ampel, N.M. (2010) Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clinical Infectious Diseases 50, 1-7.
216. Mathisen, G., Shelub, A., Truong, J., et al. (2010) Coccidioidal meningitis: clinical presentation and management in the fluconazole era. Medicine 89, 251-284.
217. Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J.N., et al. (2010) An insight into the antifungal pipeline: selected new molecules and beyond. Nature Reviews Drug Discovery 9, 719-727.
218. Rosenstein, N.E., Emery, K.W., Werner, S.B., et al. (2001) Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996. Clinical Infectious Diseases 32, 708-715.
219. Stevens, D.A., Clemons, K.V., Levine, H.B., et al. (2009) Expert opinion: what to do when there is Coccidioides exposure in a laboratory. Clinical Infectious Diseases 49, 919-923.
220. Stevens, D.A., Rendon, A., Gaona-Flores, V., et al. (2007) Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 132, 952-958.
221. Tsang, C.A., Anderson, S.M., Imholte, S.B., et al. (2010) Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007-2008. Emerging Infectious Diseases 16, 1738-1744.
222. Woods, C.W., McRill, C., Plikaytis, B.D., et al. (2000) Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. Journal of Infectious Diseases 181, 1428-1434.
223. Cano, M.V. & Hajjeh, R.A. (2001) The epidemiology of histoplasmosis: a review. Seminars in Respiratory Infections 16, 109-118.
224. Centers for Disease Control and Prevention. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 58(RR-4), 1-207.
225. Connnolly, P.A., Durkin, M.M., LeMonte, A., et al. (2007) Detection of Histoplasma antigen by a quantitative enzyme immunoassay. Clinical and Vaccine Immunology 14, 1587-1591.
226. Cuellar-Rodriguez, J., Avery, R.K., Lard, M., et al. (2009) Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clinical Infectious Diseases 49, 710-716.
227. Goldman, M., Zackin, R., Fichtenbaum, D.J., et al. (2004) Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical Infectious Diseases 38, 1490-1494.
228. Gutierrez, M.E., Canton, A., Sosa, N., et al. (2005) Disseminated histoplasmosis in patients with AIDS in Panama: a review of 104 cases. Clinical Infectious Diseases 40, 1199-1202.
229. Hage, C.A., Bowyer, S., Tarvin, S.E., et al. (2010) Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clinical Infectious Diseases 50, 85-92.
230. Hage, C.A., Ribes, J.A., Wengenack, N.L., et al. (2011) A multicenter evaluation of tests for diagnosis of histoplasmosis. Clinical Infectious Diseases 53, 448-454.
231. Kauffman, C.A. (2007) Histoplasmosis: a clinical and laboratory update. Clinical Microbiology Reviews 20, 115-132.
232. Kennedy, C.C. & Limper, A.H. (2007) Redefining the clinical spectrum of chronic pulmonary histoplasmosis. Medicine 86, 252-258.
233. Wheat, L.J., Freifeld, A.G., Kleiman, M.B., et al. (2007) Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 45, 807-825.
234. Wheat, L.J., Musial, C.E. & Jenny-Avital, E. (2005) Diagnosis and management of central nervous system histoplasmosis. Clinical Infectious Diseases 40, 844-852.
235. Ameen, M., Talhari, C. & Talhari, S. (2010) Advances in paracoccidioidomycosis. Clinical and Experimental Dermatology 35, 576-580.
236. Da Mota Menezes, V., Soares, B. & Fontes C.J. (2006) Drugs for treating paracoccidioidomycosis. Cochrane Database of Systematic Reviews CD004967.
237. De Almeida, S.M. (2005) Central nervous system paracoccidioidomycosis: an overview. Brazilian Journal of Infectious Diseases 9, 126-133.
238. De Camargo, Z.P. (2008) Serology of paracoccidioidomycosis. Mycopathologia 165, 289-302.
239. Ferreira, M.S. (2009) Paracoccidioidomycosis. Pediatric Respiratory Reviews 10, 161-165.
240. Loro Morejon, K.M., Machado, A.A. & Martinez, R. (2009) Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a casecontrol study. American Journal of Tropical Medicine and Hygiene 80, 359-366.
241. Queiroz-Telles, F., Goldani, L.Z., Schlamm, H.T., et al. (2007) An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clinical Infectious Diseases 45, 1462-1469.
242. Restrepo, A., Benard, G., De Castro, C.C., et al. (2008) Pulmonary paracoccidioidomycosis. Seminars in Respiratory and Critical Care Medicine 29, 182-197.
243. Shikanai-Yasuda, M.A. (2005) Pharmacological management of paracoccidioidomycosis. Expert Opinion in Pharmacotherapy 6, 385-397.
244. Shikanai-Yasuda, M.A., Benard, G., Higaki, Y., et al. (2002) Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. Medical Mycology 40, 11-17.
245. Ameen, M. (2009) Chromoblastomycosis: clinical presentation and management. Clinical and Experimental Dermatology 34, 849-854.
246. Bonifaz, A., Carrasco-Gerard, E. & Saul, A. (2001) Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses 44, 1-7.
247. Lopez-Martinez, R. & Mendez-Tovar, L.J. (2007) Chromoblastomycosis. Clinics in Dermatology 25, 188-194.
248. Minotto, R., Bernardi, C.D., Mallmann, L.F., et al. (2001) Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. Journal of the American Academy of Dermatology 44, 585-592.
249. Negroni, R., Tobon, A., Bustamante, B., et al. (2005) Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Revista do Instituto de Medicina Tropical de Sao Paulo 47, 339-346.
250. Queiroz-Telles, F., Esterre, P., Perez-Blanco, M., et al. (2009) Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Medical Mycology 47(special issue), 3-15.
251. Bigliazzi, C., Poletti, V., Dell'Amore, D., et al. (2004) Disseminated basidiobolomycosis in an immunocompetent woman. Journal of Clinical Microbiology 42, 1367-1369.
252. Gugani, H.C. (1992) Entomophthoromycosis due to Conidiobolus. European Journal of Epidemiology 8, 391-396.
253. Gugnani, H.C. (1999) A review of zygomycosis due to Basidiobolus ranarum. European Journal of Epidemiology 15, 923-929.
254. Lyon, G.M., Smilack, J.D., Komatsu, K.K., et al. (2001) Gastrointestinal basidiobolomycosis in Arizona: clinical and epidemiological characteristics and review of the literature. Clinical Infectious Diseases 32, 1448-1455.
255. Nemenqani, D., Yaqoob, N., Khoja, H., et al. (2009) Gastrointestinal basidiobolomycosis: an unusual fungal infection mimicking colon cancer. Archives of Pathology and Laboratory Medicine 133, 1938-1942.
256. Ribes, J.A., Vanover-Sams, C.L. & Baker, D.J. (2000) Zygomycetes in human disease. Clinical Microbiology Reviews 13, 236-301.
257. Wuppenhorst, N., Lee, M.-K., Rappold, E., et al. (2010) Rhino-orbitocerebral zygomycosis caused by Conidiobolus incongruus in an immunocompromised patient in Germany. Journal of Clinical Microbiology 48, 4322-4325.
258. Ahmed, A., Adelmann, D., Fahal, A., et al. (2002) Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudan. Journal of Clinical Microbiology 40, 1031-1036.
259. Ameen, M. & Arenas, R. (2008) Developments in the management of mycetomas. Clinical and Experimental Dermatology 34, 1-7.
260. Ameen, M. & Arenas, R. (2008) Emerging therapeutic regimes for the management of mycetomas. Expert Opinion in Pharmacotherapy 9, 2077-2085.
261. Czechowski, J., Nork, M., Haas, D., et al. (2001) MR and other imaging methods in the investigation of mycetomas. Acta Radiologica 42, 24-26.
262. Desnos-Ollivier, M., Bretagne, S., Dromer, F., et al. (2006) Molecular identification of black-grain mycetoma agents. Journal of Clinical Microbiology 44, 3517-3523.
263. Garnica, M., Nucci, M. & Queiroz-Telles, F. (2009) Difficult mycoses of the skin: advances in the epidemiology and management of eumycetoma, phaeohyphomycosis and chromoblastomycosis. Current Opinion in Infectious Diseases 22, 559-563.
264. Negroni, R., Tobon, A., Bustamante, B., et al. (2005) Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Revista do Instituto de Medicina Tropical de Sao Paulo 47, 339-346.
265. Welch, O., Vera-Cabrera, L. & Salinas-Carmona, M. (2007) Mycetoma. Clinics in Dermatology 25, 195-202.
266. De Lima Barros, M.B., De Almeida Paes, R. & Schubach, A.O. (2011) Sporothrix schenckii and sporotrichosis. Clinical Microbiology Reviews 24, 633-654.
267. De Lima Barros, M.B., Schubach, A.O., Carvalhaes de Oliveira, R., et al. (2011) Treatment of cutaneous sprotrichosis with itraconazole: study of 645 patients. Clinical Infectious Diseases 52, e200-e206.
268. Hardman, S., Stephenson, I., Jenkins, D.R., et al. (2005) Disseminated Sporothrix schenckii in a patient with AIDS. Journal of Infection 51, e73-e77.
269. Hay, R.J. & Morris-Jones, R. (2008) Outbreaks of sporotrichosis. Current Opinion in Infectious Diseases 21, 119-121.
270. Kauffman, C.A., Bustamante, B., Chapman, S.W., et al. (2007) Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 45, 1255-1265.
271. Lyon, G.M., Zurita, S., Casquero, J., et al. (2003) Population-based surveillance and a case-control study of risk factors for endemic lymphocutaneous sporotrichosis in Peru. Clinical Infectious Diseases 36, 34-39.
272. Marimon, R., Cano, J., Gene, J., et al. (2006) Molecular phylogeny of Sporothrix schenckii. Journal of Clinical Microbiology 44, 3251-3256.
273. Quintal, D. (2000) Sporotrichosis infection on mines of the Witwatersrand. Journal of Cutaneous Medicine and Surgery 4, 51-54.
274. Ramos-e-Silva, M., Vasconcelos, C., Carneiro, S., et al. (2007) Sporotrichosis. Clinics in Dermatology 25, 181-187.
275. Xue, S., Gu, R., Wu, T., et al. (2009) Oral potassium iodide for the treatment of sporotrichosis. Cochrane Database of Systematic Reviews CD006136.
276. Anaissie, E.J., Kuchar, R.T., Rex, J.H., et al. (2001) Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clinical Infectious Diseases 33, 1871-1878.
277. Campo, M., Lewis, R.E. & Kontoyiannis, D.K. (2010) Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. Journal of Infection 60, 331-337.
278. Carneiro, H.A., Coleman, J.J., Restrepo, A., et al. (2011) Fusarium infection in lung transplant recipients: report of 6 cases and review of the literature. Medicine (Baltimore) 90, 69-80.
279. Cimon, B., Carrere, J., Vinatier, J.F., et al. (2000) Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. European Journal of Clinical Microbiology and Infectious Diseases 19, 53-56.
280. Cortez, K.J., Roilides, E., Quiroz-Telles, F., et al. (2008) Infections caused by Scedosporium spp. Clinical Microbiology Reviews 21, 157-197.
281. Gilgado, F., Cano, J., Gene, J., et al. (2008) Molecular and phenotypic data supporting distinct species statuses for Scedosporium apiospermum and Pseudallescheria boydii and the proposed new species Scedosporium dehoogii. Journal of Clinical Microbiology 46, 766-771.
282. Husain, S., Munoz, P., Forrest, G., et al. (2005) Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal therapy on outcome. Clinical Infectious Diseases 40, 89-99.
283. Lamaris, G.A., Chamilos, G., Lewis, R.E., et al. (2006) Scedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989-2006. Clinical Infectious Diseases 43, 1580-1584.
284. Lortholary, O., Obenga, G., Biswas, P., et al. (2010) International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrobial Agents and Chemotherapy 54, 4446-4450.
285. Lu, Q., Gerrits van den Ende, A.H., Bakkers, J.M., et al. (2011) Identification of Pseudallescheria and Scedosporium species by three molecular methods. Journal of Clinical Microbiology 49, 960-967.
286. Marom, E.M., Holmes, A.M., Bruzzi, J.F., et al. (2008) Imaging of pulmonary fusariosis in patients with hematologic malignancies. American Journal of Roentgenology 190, 1605-1609.
287. Morio, F., Horeau-Langlard, D., Gay-Andrieu, F., et al. (2010) Disseminated Scedosporium/Pseudallescheria infection after double lung transplantation in patients with cystic fibrosis. Journal of Clinical Microbiology 48, 1978-1982.
288. Nucci, M. & Anaissie, E. (2002) Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clinical Infectious Diseases 35, 909-920.
289. Nucci, M. & Anaissie, E. (2007) Fusarium infections in immunocompromised patients. Clinical Microbiology Reviews 20, 695-704.
290. Nucci, M., Marr, K.A., Queiroz-Telles, F., et al. (2004) Fusarium infection in hematopoietic stem cell transplant recipients. Clinical Infectious Diseases 38, 1237-1242.
291. O'Donnell, K., Sutton, D.A., Rinaldi, M.G., et al. (2010) Internet-accessible DNA sequence database for identifying Fusaria from human and animal infections. Journal of Clinical Microbiology 48, 3708-3718.
292. Pastor, F.J. & Guarro, J. (2006) Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clinical Microbiology and Infection 12, 948-960.
293. Perdomo, H., Sutton, D.A., Garcia, D., et al. (2011) Spectrum of clinically relevant Acremonium species in the United States. Journal of Clinical Microbiology 49, 243-256.
294. Raad, I.I., Hachem, R.Y., Herbrecht, R., et al. (2006) Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clinical Infectious Diseases 42, 1398-1403.
295. Troke, P.F., Aguirrebengoa, K., Arteaga, C., et al. (2008) Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrobial Agents and Chemotherapy 52, 1743-1750.
296. Antinori, S., Gianelli, E., Bonaccorso, C., et al. (2006) Disseminated Penicillium marneffei infection in an HIV-positive Italian patient and a review of cases reported outside endemic regions. Journal of Travel Medicine 13, 181-188.
297. Centers for Disease Control and Prevention. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morbidity and Mortality Weekly Report 58 (RR-4), 1-207.
298. Chariyalertsak, S., Sirisanthana, T., Saengwonloey, O., et al. (2001) Clinical presentation and risk behaviors of AIDS patients in Thailand, 1994-1998: regional variation and temporal trends. Clinical Infectious Diseases 32, 955-962.
299. Huang, Y.T., Hung, C.C., Liao, C.H., et al. (2007) Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. Journal of Clinical Microbiology 45, 2858-2862.
300. Le, T., Chi, N.H., Cuc, N.T., et al. (2010) AIDS-associated Penicillium marneffei infection of the central nervous system. Clinical Infectious Diseases 51, 1458-1462.
301. Le, T., Wolbers, M., Chi, N.H., et al. (2011) Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clinical Infectious Diseases 52, 945-952.
302. Supparatpinyo, K. & Schlamm, H.T. (2007) Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. American Journal of Tropical Medicine and Hygiene 77, 350-353.
303. Ustianowski, A.P., Sieu, T.P. & Day, J.N. (2008) Penicillium marneffei infection in HIV. Current Opinion in Infectious Diseases 21, 31-36.
304. Vanittanakom, N., Cooper, C.R., Fisher, M.C., et al. (2006) Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clinical Microbiology Reviews 19, 95-110.
305. Wong, S.Y.&Wong, K.F. (2011) Penicillium marneffei infection in AIDS. Pathology Research International 2011, 764293.
306. Al-Abdely, H.M., Alkhunaiz, A.M., Al-Tawfiq, J.A., et al. (2005) Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Medical Mycology 43, 91-95.
307. Ben-Ami, R., Lewis, R.E., Raad, I.I., et al. (2009) Phaeohyphomycosis in a tertiary care cancer center. Clinical Infectious Diseases 48, 1033-1041.
308. Brandt, M.E. & Warnock, D.W. (2003) Epidemiology, clinical manifestations and therapy of infections caused by dematiaceous fungi. Journal of Chemotherapy 15(Suppl. 2), 36-47.
309. Chakrabarti, A., Denning, D.W., Ferguson, B.J., et al. (2009) Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope 119, 1809-1818.
310. Cortez, K.J., Roilides, E., Quiroz-Telles, F., et al. (2008) Infections caused by Scedosporium spp. Clinical Microbiology Reviews 21, 157-197.
311. Husain, S., Munoz, P., Forrest, G., et al. (2005) Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal therapy on outcome. Clinical Infectious Diseases 40, 89-99.
312. Jabeen, K., Farooqi, J., Zafar, A., et al. (2011) Rhinocladiella mackenziei as an emerging cause of cerebral phaeohyphomycosis in Pakistan: a case series. Clinical Infectious Diseases 52, 213-217.
313. Lyons, M.K., Blair, J.E. & Leslie, K.O. (2005) Successful treatment with voriconazole of fungal cerebral abscess due to Cladophialophora bantiana. Clinical Neurology and Neurosurgery 107, 532-534.
314. Nucci, M., Akiti, T., Barreiros, G., et al. (2002) Nosocomial outbreak of Exophiala jeanselmei fungemia associated with contamination of hospital water. Clinical Infectious Diseases 34, 1475-1480.
315. Revankar, S.G., Patterson, J.E., Sutton, D.A., et al. (2002) Disseminated phaeohyphomycosis: review of an emerging mycosis. Clinical Infectious Diseases 34, 467-476.
316. Revankar, S.G. & Sutton, D.A. (2010) Melanized fungi in human disease. Clinical Microbiology Reviews 23, 884-928.
317. Revankar, S.G., Sutton, D.A. & Rinaldi, M.G. (2004) Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clinical Infectious Diseases 38, 206-216.
318. Rodriguez-Tudela, J.L., Berenguer, J., Guarro, J., et al. (2009) Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Medical Mycology 47, 359-370.
319. Taj-Aldeen, S.J., Almaslaman, M., Alkhal, A., et al. (2010) Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): a taxonomic update and review of the literature. Medical Mycology 48, 546-556.
320. Chagas-Neto, T.C., Chaves, G.M. & Colombo, A.L. (2008) Update on the genus Trichosporon. Mycopathologia 166, 121-132.
321. Chang, H.J., Miller, H.L., Watkins, N., et al. (1998) An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers' pet dogs. New England Journal of Medicine 338, 706-711.
322. Enache-Angoulvant, A. & Hennequin, C. (2005) Invasive Saccharomyces infection: a comprehensive review. Clinical Infectious Diseases 41, 1559-1568.
323. Garcia-Suarez, J., Gomez-Herruz, P., Cuadros, J.A., et al. (2010) Epidemiology and outcome of Rhodotorula infection in haematological patients. Mycoses 54, 318-324.
324. Girmenia, C., Pagano, L., Martino, B., et al. (2005) Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with haematological malignancies: a retrospective multicenter study from Italy and review of the literature. Journal of Clinical Microbiology 43, 1818-1828.
325. Lacasse, A. & Cleveland, K.O. (2008) Trichosporon mucoides fungemia in a liver transplant recipient: case report and review. Transplant Infectious Diseases 11, 155-159.
326. Martino, R., Salavert, M., Parody, R., et al. (2004) Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clinical Infectious Diseases 38, 335-341.
327. Munoz, P., Bouza, E., Cuenca-Estrella, M., et al. (2005) Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clinical Infectious Diseases 40, 1625-1634.
328. Perniola, R., Faneschi, M.L., Manso, E., et al. (2006) Rhodotorula mucilaginosa outbreak in neonatal intensive care unit: microbiological features, clinical presentation, and analysis of related variables. European Journal of Clinical Microbiology and Infectious Diseases 25, 193-196.
329. Tragiannidis, A., Bisping, G., Koehler, G., et al. (2009) Minireview: Malassezia infections in immunocompromised patients. Mycoses 53, 187-195.
330. Tuon, F.F., Duboc de Almeida, M. & Costa, S.F. (2007) Central venous catheterassociated fungemia due to Rhodotorula spp: a systematic review. Medical Mycology 45, 441-447.
331. Burns, R.A., Roy, J.S.,Woods, C., et al. (2000) Report of the first human case of lobomycosis in the United States. Journal of Clinical Microbiology 38, 1283-1285.
332. Denson, J.L., Keen, C.E., Froeschle, P.O., et al. (2009) Adiaspiromycosis mimicking widespread malignancy in a patient with pulmonary adenocarcinoma. Journal of Clinical Pathology 62, 837-839.
333. England, D.M. & Hochholzer, L. (1993) Adiaspiromycosis: an unusual fungal infection of the lung. Report of 11 cases. American Journal of Surgical Pathology 17, 876-886.
334. Gori, S., Drouhet, E., Gueho, E., et al. (1998) Cutaneous disseminated mycosis in a patient with AIDS due to a new dimorphic fungus. Journal de Mycologie Medicale 8, 57-63.
335. Herr, R.A., Ajello, L., Taylor, J.W., et al. (1999) Phylogenetic analysis of Rhinosporidium seeberi's 18S small-subunit ribosomal DNA groups this pathogen among members of the protoctistan Mesomycetozoa clade. Journal of Clinical Microbiology 37, 2750-2754.
336. Krajaejun, T., Sathapatayavongs, B., Pracharktam, R., et al. (2006) Clinical and epidemiological analyses of human pythiosis in Thailand. Clinical Infectious Diseases 43, 569-576.
337. Lupi, O., Tyring, S.K. & McGinnis, M.R. (2005) Tropical dermatology: fungal tropical diseases. Journal of the American Academy of Dermatology 53, 931-951.
338. Mendes, M.O., Moraes, M.A., Renoiner, E.I., et al. (2009) Acute conjunctivitis with episcleritis and anterior uveitis linked to adiaspiromycosis and freshwater sponges, Amazon region, Brazil, 2005. Emerging Infectious Diseases 15, 633-639.
339. Mendoza, L., Prasla, S.H. & Ajello, L. (2004) Orbital pythiosis: a non-fungal disease mimicking orbital mycotic infections, with a retrospective review of the literature. Mycoses 47, 14-23.
340. Pelegrin, I., Ayats, J., Xiol, X., et al. (2011) Disseminated adiaspiromycosis: case report of a liver transplant patient with human immunodeficiency infection, and literature review. Transplant Infectious Diseases 13, 507-514.
341. Pfaller, M.A. & Diekema, D.J. (2005) Unusual fungal and pseudofungal infections of humans. Journal of Clinical Microbiology 43, 1495-1504.
342. Vukovic, Z., Bobic-Radovanovic, A., Latkovic, Z., et al. (1995) An epidemiological investigation of the first outbreak of rhinosporidiosis in Europe. Journal of Tropical Medicine and Hygiene 98, 333-337.
343. Anaissie, E.J., McGinnis, M.R. & Pfaller, M.A. (eds) (2009) Clinical Mycology, 2nd edn. Churchill Livingstone Elsevier, Philadelphia.
344. Hospenthal, D.R. & Rinaldi, M.G. (eds) (2008) Diagnosis and Treatment of Human Mycoses. Humana Press, Totowa, NJ.
345. Kaufmann, C.A., Pappas, P.G., Sobel, J.D. & Dismukes, W.E. (eds) (2011) Essentials of Clinical Mycology, 2nd edn. Springer, New York.
346. Barnes, R.A. & Warnock, D.W. (eds) (2002) Fungal Infection in the Intensive Care Unit. Kluwer Academic Publishers, Norwell, MA.
347. Heitman, J., Filler, S.G., Edwards, J.E. & Mitchell, A.P. (eds) (2006) Molecular Principles of Fungal Pathogenesis. ASM Press,Washington, DC.
348. Wingard, J.R. & Anaissie, E.J. (eds) (2005) Fungal Infections in the Immunocompromised Patient. Taylor and Francis, Boca Raton, FL.
349. Ghannoum, M.A. & Perfect, J.R. (eds) (2010) Antifungal Therapy. Informa Healthcare, New York.
350. Calderone, R.A. & Clancy, C.J. (eds) (2011) Candida and Candidiasis, 2nd edn. ASM Press, Washington, DC.
351. Heitman, J., Kozel, T.R., Kwon-Chung, K.J., Perfect, J.R. & Casadevall, A. (eds) (2011) Cryptococcus: From Human Pathogen to Model Yeast. ASM Press,Washington, DC.
352. Latgé, J.-P. & Steinbach, W.J. (eds) (2009) Aspergillus fumigatus and Aspergillosis. ASM Press,Washington, DC.
353. Pasqualotto, A.C. (ed.) (2010) Aspergillosis: from Diagnosis to Prevention. Springer, Dordrecht.
354. Kauffman, C.A. (ed.) (2011) Atlas of Fungal Infections, 2nd edn. Current Medicine Group, New York.
355. Maertens, J.A. & Marr, K.A. (eds) (2007) Diagnosis of Fungal Infections. Informa Healthcare, New York.
356. Versalovic, J., Carroll, K.C., Funke, G., Jorgensen, J.H., Landry, M.L. & Warnock, D.W. (eds) (2011) Manual of Clinical Microbiology, 10th edn. ASM Press,Washington, DC.
357. Larone, D.H. (2011) Medically Important Fungi: A Guide to Identification, 5th edn. ASM Press,Washington, DC.
358. St-Germain, G. & Summerbell, R. (2011) Identifying Fungi: A Clinical Laboratory Handbook, 2nd edn. Star Publishing, Belmont, CA.
359. Richardson, M.D. & Johnson, E.M. (2006) Pocket Guide to Fungal Infection, 2nd edn. Blackwell Publishing, Oxford.
360. Richardson, M.D., Jones, B.L. & Rautemaa, R. (2007) Therapeutic Guidelines in Systemic Fungal Infections, 4th edn. Remedica, London.
361. http://www.aspergillus.man.ac.uk/
362. http://www.cdc.gov
363. http://www.cher.ubc.ca/cryptococcus/new/default.htm
364. http://www.clinicaltrials.gov
365. http://www.doctorfungus.org
366. http://www.isham.org
367. http://www.mycology.adelaide.edu.au